Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $1.58 billion
- Book Value:
- Revenue TTM:
- $296.54 million
- Operating Margin TTM:
- Gross Profit TTM:
- $194.95 million
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Veracyte Inc had its IPO on 2013-10-30 under the ticker symbol VCYT.
The company operates in the Healthcare sector and Biotechnology industry. Veracyte Inc has a staff strength of 787 employees.
Shares of Veracyte Inc opened at $21.88 at the start of the last trading session i.e. 2023-03-24.
The stocks traded within a range of $21.3 - $22.17, and closed at $21.97.
This is a -0.68% slip from the previous day's closing price.
A total volume of 672,113 shares were traded at the close of the day’s session.
In the last one week, shares of Veracyte Inc have slipped by -5.75%.
Veracyte Inc's Key Ratios
Veracyte Inc has a market cap of $1.58 billion, indicating a price to book ratio of 1.9941 and a price to sales ratio of 7.1658.
In the last 12-months Veracyte Inc’s revenue was $296.54 million with a gross profit of $194.95 million and an EBITDA of $-11699000. The EBITDA ratio measures Veracyte Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Veracyte Inc’s operating margin was -12.69% while its return on assets stood at -2.01% with a return of equity of -3.37%.
In Q4, Veracyte Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 19.2%.
Veracyte Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-0.51 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Veracyte Inc’s profitability.
Veracyte Inc stock is trading at a EV to sales ratio of 6.8297 and a EV to EBITDA ratio of -106.0056. Its price to sales ratio in the trailing 12-months stood at 7.1658.
Veracyte Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $1.16 billion
- Total Liabilities
- $62.61 million
- Operating Cash Flow
- Capital Expenditure
- $1.87 million
- Dividend Payout Ratio
Veracyte Inc ended 2023 with $1.16 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $1.16 billion while shareholder equity stood at $1.08 billion.
Veracyte Inc ended 2023 with $4.53 million in deferred long-term liabilities, $62.61 million in other current liabilities, 72000.00 in common stock, $-393717000.00 in retained earnings and $695.89 million in goodwill. Its cash balance stood at $154.25 million and cash and short-term investments were $178.85 million. The company’s total short-term debt was $4,070,000 while long-term debt stood at $0.
Veracyte Inc’s total current assets stands at $248.64 million while long-term investments were $0 and short-term investments were $24.61 million. Its net receivables were $44.02 million compared to accounts payable of $11.91 million and inventory worth $14.29 million.
In 2023, Veracyte Inc's operating cash flow was $-26434000.00 while its capital expenditure stood at $1.87 million.
Comparatively, Veracyte Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Veracyte Inc stock is currently trading at $21.97 per share. It touched a 52-week high of $32.4 and a 52-week low of $32.4. Analysts tracking the stock have a 12-month average target price of $31.67.
Its 50-day moving average was $24.55 and 200-day moving average was $22.97 The short ratio stood at 5.11 indicating a short percent outstanding of 0%.
Around 96.9% of the company’s stock are held by insiders while 10474% are held by institutions.
Frequently Asked Questions About Veracyte Inc
Similar Industry Stocks (Biotechnology)
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.